Cell therapy and gene therapy are related fields that often overlap. Cell therapy works by restoring or modifying cells, or using them to deliver treatments, and these cells are prepared outside the body before being given to the patient. They can be derived from the patient (autologous) or a donor (allogeneic). Gene therapy, on the other hand, treats disease by replacing, turning off, or adding genes to cells, either directly in the body (in vivo) or outside the body (ex vivo). Both types of therapy rely on the cells maintaining their integrity, viability, and function throughout manufacturing and delivery.
Driven by advances in science and growing clinical demand, the global cell and gene therapy market, valued at $27.02 billion in 2025, is projected to reach approximately $232.22 billion by 2035, growing at a 24% compound annual growth rate, according to a study by Towards Healthcare, a sister firm of Precedence Research.
For comments and feedback: editorial@rttnews.com